Literature DB >> 25520879

Methylation of ras association domain protein 10 (RASSF10) promoter negative association with the survival of gastric cancer.

Jingyu Deng1, Han Liang1, Guoguang Ying2, Haixin Li3, Xingming Xie1, Jun Yu4, Daiming Fan5, Xishan Hao1.   

Abstract

OBJECTIVE: The present study was conducted to elucidate the prognostic prediction value of the methylation of the RASSF10 promoter in gastric cancer (GC).
METHODS: A total of 300 patients with GC revealed the methylation degrees of the DNA of the RASSF10 promoter. Methylation-specific PCR (MSP) analysis was performed to qualitatively detect the methylated degrees of the DNA of the RASSF10 promoter of 300 patients with GC. Associations between molecular, clinicopathological and survival data were analyzed.
RESULTS: The protein and mRNA expressions of RASSF10 in GC tissues were lower than those in normal gastric mucosal tissues. In the MSP analysis cohort, patients with methylated RASSF10 promoter exhibited significantly shorter median OS than those with unmethylated RASSF10 promoter (P < 0.001). Multivariate survival analysis results showed that methylated RASSF10 promoter was an independent predictor of the survival of patients with GC.
CONCLUSIONS: The methylation of the RASSF10 promoter could be applied for the clinical prediction of the prognosis of GC.

Entities:  

Keywords:  Stomach; methylation; neoplasm; ras association domain protein; survival

Year:  2014        PMID: 25520879      PMCID: PMC4266723     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  18 in total

Review 1.  The fundamental role of epigenetic events in cancer.

Authors:  Peter A Jones; Stephen B Baylin
Journal:  Nat Rev Genet       Date:  2002-06       Impact factor: 53.242

2.  Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes.

Authors:  Zhi Jiang Zang; Ioana Cutcutache; Song Ling Poon; Shen Li Zhang; John R McPherson; Jiong Tao; Vikneswari Rajasegaran; Hong Lee Heng; Niantao Deng; Anna Gan; Kiat Hon Lim; Choon Kiat Ong; DaChuan Huang; Sze Yung Chin; Iain Beehuat Tan; Cedric Chuan Young Ng; Willie Yu; Yingting Wu; Minghui Lee; Jeanie Wu; Dianne Poh; Wei Keat Wan; Sun Young Rha; Jimmy So; Manuel Salto-Tellez; Khay Guan Yeoh; Wai Keong Wong; Yi-Jun Zhu; P Andrew Futreal; Brendan Pang; Yijun Ruan; Axel M Hillmer; Denis Bertrand; Niranjan Nagarajan; Steve Rozen; Bin Tean Teh; Patrick Tan
Journal:  Nat Genet       Date:  2012-05       Impact factor: 38.330

3.  RASSF10 is epigenetically silenced and functions as a tumor suppressor in gastric cancer.

Authors:  Ziran Wei; Xia Chen; Ji Chen; Weimin Wang; Xudong Xu; Qingping Cai
Journal:  Biochem Biophys Res Commun       Date:  2013-02-19       Impact factor: 3.575

4.  RASSF10 is an epigenetically silenced tumor suppressor in gastric cancer.

Authors:  Zhenhua Li; Xiaojing Chang; Dongqiu Dai; Peng Deng; Qiang Sun
Journal:  Oncol Rep       Date:  2014-02-20       Impact factor: 3.906

5.  Frequent epigenetic inactivation of RASSF10 in thyroid cancer.

Authors:  Undraga Schagdarsurengin; Antje M Richter; Christina Wöhler; Reinhard H Dammann
Journal:  Epigenetics       Date:  2009-11-14       Impact factor: 4.528

Review 6.  Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?

Authors:  Stephen B Baylin; Joyce E Ohm
Journal:  Nat Rev Cancer       Date:  2006-02       Impact factor: 60.716

Review 7.  N-terminal RASSF family: RASSF7-RASSF10.

Authors:  Nicholas Underhill-Day; Victoria Hill; Farida Latif
Journal:  Epigenetics       Date:  2011-03-01       Impact factor: 4.528

8.  Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types.

Authors:  Siân Jones; Meng Li; D Williams Parsons; Xiaosong Zhang; Jelle Wesseling; Petra Kristel; Marjanka K Schmidt; Sanford Markowitz; Hai Yan; Darell Bigner; Ralph H Hruban; James R Eshleman; Christine A Iacobuzio-Donahue; Michael Goggins; Anirban Maitra; Sami N Malek; Steve Powell; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Hum Mutat       Date:  2011-11-23       Impact factor: 4.878

9.  Frequent gene amplification predicts poor prognosis in gastric cancer.

Authors:  Jing Shi; Demao Yao; Wei Liu; Na Wang; Hongjun Lv; Nongyue He; Bingyin Shi; Peng Hou; Meiju Ji
Journal:  Int J Mol Sci       Date:  2012-04-13       Impact factor: 6.208

10.  Combined RASSF1A and RASSF2A Promoter Methylation Analysis as Diagnostic Biomarker for Bladder Cancer.

Authors:  Wei Meng; Alexander Huebner; Ahmad Shabsigh; Arnab Chakravarti; Tim Lautenschlaeger
Journal:  Mol Biol Int       Date:  2012-03-11
View more
  3 in total

1.  The value of serum RASSF10 hypermethylation as a diagnostic and prognostic tool for gastric cancer.

Authors:  Wan-Jiang Xue; Ying Feng; Fei Wang; Peng Li; Yi-Fei Liu; Yi-Bing Guo; Zhi-Wei Wang; Qin-Sheng Mao
Journal:  Tumour Biol       Date:  2016-03-05

2.  Lower expression of PH domain leucine-rich repeat protein phosphatase 1 (PHLPP1) association with poor prognosis of gastric cancer.

Authors:  Yachao Hou; Jingyu Deng; Li Zhang; Xingming Xie; Xiaofan Guo; Changyu Sun; Rupeng Zhang; Han Liang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

3.  Integration of intratumoral RASSF10 expression and tumor-associated macrophages into the established clinical indicators better predicts the prognosis of clear cell renal cell carcinoma patients.

Authors:  Chao Wang; Tianyu Hong; Yuning Wang; Sishun Gan; Qifeng Wang; Jian Li; Li Zuo; Xingang Cui
Journal:  Oncoimmunology       Date:  2020-03-11       Impact factor: 8.110

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.